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n Evidence summary
Our comprehensive literature search 
found no studies that provide direct evi-
dence for or against continuing to moni-
tor microalbuminuria among patients 
with diabetes already on ACE inhibitor 
or ARB therapy. We reviewed and includ-
ed indirect evidence and expert opinion 
to answer this clinical question. 
Diabetes mellitus is the leading 
cause of end-stage renal disease in the 
Western world.1 The prevalence of 
diabetic nephropathy continues to rise 
along with the rapidly rising prevalence 
of obesity and diabetes, with 40% of 
patients with diabetes at risk of de-
veloping nephropathy. One study that 
followed 5097 patients with type 2 
diabetes over a median of 10.4 years 
found that 2% of patients progressed 
from normal levels of urinary protein 
to microalbuminuria; 2.8% changed 
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e v i d e n c e - b a s e d  a n s w e r
No	 studies	 address	 whether	 continued	
screening	 for	 microalbuminuria	 once	 a	
patient	is	taking	an	angiotensin-converting	
enzyme	 (aCe)	 inhibitor	 or	 angiotensin-2	
receptor	 blocker	 (arb)	 improves	 out-
comes.	 Indirect	 evidence	 and	 expert	
opinion	suggest	that	 it	may	be	beneficial	
to	 continue	 microalbuminuria	 surveil-
lance	to	assess	response	to	therapy	and	
monitor	 disease	 progression	 (strength	
of	 recommendation:	C,	 based	 on	 expert	
opinion).
c l i n i c a l  c o m m e n t a r y
It is unclear whether microalbuminuria 
tests in these cases is money well spent
at	the	residency	where	I	teach,	clinicians	
routinely	 try	 to	 get	 to	 the	 evidence	 be-
hind	 the	expert	opinions,	and	 faculty	are	
discouraged	from	giving	off	the	cuff	or	ex-
periential	 answers.	When	 asked	whether	
to	 monitor	 microalbuminuria	 for	 patients	
with	 diabetes	 receiving	 aCe	 inhibitors	
or	arbs,	 it	 is	 frustrating	 to	discover	 that	
no	direct	evidence	supports	 the	experts’	
advice.	
The	screening	test	for	urine	microalbu-
minuria	 at	 our	 hospital	 costs	 $90.	 since	
most	 patients	 with	 diabetes	 are	 being	
treated	 with	 aCe	 inhibitors	 or	 arbs,	 it	
would	be	nice	to	know	that	the	money	for	
the	 testing	 is	 well	 spent.	 unfortunately,	
in	 this	 instance,	we	can	only	continue	 to	
practice	the	“standard	of	care”	and	hope	
for	 future	 research	 to	 definitively	 answer	
this	question.
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from microalbuminuria to macroalbu-
minuria (urine albumin >300 mg in a 
24-hour period); and 2.3% progressed 
to chronic renal disease (creatinine 
≥2 mg/dL) from macroalbuminuria per 
year.2 Chronic renal disease is more 
likely to occur in those patients whose 
hypertension or hyperglycemia is poor-
ly controlled. 
For patients with diabetes who de-
velop microalbuminuria, the evidence 
is good for starting ACE inhibitors or 
ARBs for renal protection.3,4 The Amer-
ican Diabetes Association (ADA) also 
recommends that patients with diabetes 
and hypertension and those aged >55 
years with other cardiovascular risk fac-
tors (history of cardiovascular disease, 
dyslipidemia, or tobacco use) be started 
on ACE inhibitors or ARBs.1 There is 
also good evidence that screening for 
microalbuminuria can identify those 
who might benefit from treatments that 
delay the onset of nephropathy.5 
Recent studies have raised the pos-
sibility of further benefit in prevention 
and treatment of diabetic nephropathy 
by maximizing doses of ACE inhibitors 
or ARBs, and even from the dual block-
ade attained from using both. For ex-
ample, during a 2-year trial—in which 
590 patients with diabetes and microal-
buminuria were randomized to receive 
placebo, 150 mg irbesartan, or 300 
mg irbesartan—14.9% of the placebo 
group, 9.7% of the 150-mg group, and 
only 5.2% of the 300-mg group pro-
gressed to overt nephropathy.6 In very 
small randomized trial of 20 patients 
with type 2 diabetes, adding 16 mg of 
candesartan to the maximal dose of an 
ACE inhibitor decreased albuminuria 
an additional 28%.7 
Experts argue that it may benefit 
patients to continue regular surveil-
lance for the presence or progression of 
microalbuminuria even if they are al-
ready taking an ACE inhibitor or ARB 
so that therapy can be maximized.1,8 
However, no direct evidence supports 
this recommendation.
Recommendations from others
The ADA suggests that clinicians per-
form a test each year for microalbu-
minuria among patients with type 1 
diabetes of ≥5 years duration, and in all 
patients with type 2 diabetes at diag-
nosis and during pregnancy. They also 
recommend continued surveillance of 
proteinuria to assess both response to 
therapy and progression of disease.1
The National Kidney Foundation 
recommends continued surveillance of 
microalbuminuria to assess progression 
of chronic kidney disease and response 
to therapy.8
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Experts call for 
microalbuminuria 
surveillance to 
assess response to 
therapy,  
but no evidence 
supports this
